Side effects and watch-outs
- HPTA suppression
- LFTs required
- HDL suppression
- Back acne
- Most human safety data of any SARM — but still unapproved
SARM / Classic SARM
Enobosarm (GTx-024)
Pharmaceutical name for Ostarine (MK-2866). Phase 3 trials for cancer cachexia. Failed FDA approval in 2013 (missed endpoint) but Phase 3 data makes it most-studied SARM.
Educational reference only. This page does not diagnose, prescribe, or replace care from a licensed professional. Laws, availability, and clinical appropriateness vary by location.